nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

02.05.2020 | Letter to the Editor

Optimal image guidance for tumor biopsy in non-small-cell lung cancer

verfasst von: Liang Zhao, Qin Lin, Haojun Chen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04500-7.

Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, et al. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71–7. https://doi.org/10.1016/j.lungcan.2018.03.001.CrossRefPubMed

Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer. 2018;101:181–90. https://doi.org/10.1016/j.ejca.2018.06.022.CrossRefPubMed

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43(11):1954–61. https://doi.org/10.1007/s00259-016-3425-2.CrossRefPubMed

Levy EB, Fiel MI, Hamilton SR, Kleiner DE, McCall SJ, Schirmacher P, et al. State of the art: toward improving outcomes of lung and liver tumor biopsies in clinical trials-a multidisciplinary approach. J Clin Oncol. 2020:JCO1902322. https://doi.org/10.1200/JCO.19.02322.

Purandare NC, Kulkarni AV, Kulkarni SS, Roy D, Agrawal A, Shah S, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013;34(3):203–10. https://doi.org/10.1097/MNM.0b013e32835c5a57.CrossRefPubMed

Cho A, Hur J, Kang WJ, Cho HJ, Lee JH, Yun M, et al. Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol. 2011;21(5):1077–87. https://doi.org/10.1007/s00330-010-2006-1.CrossRefPubMed

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. https://doi.org/10.1093/annonc/mdv489.CrossRefPubMed

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. https://doi.org/10.1016/j.cell.2012.03.017.CrossRefPubMedPubMedCentral

10.

Evangelista L. The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. J Thorac Dis. 2019;11(11):E221–E3. https://doi.org/10.21037/jtd.2019.10.19.CrossRefPubMedPubMedCentral

11.

Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol. 2019;54(1):370–80. https://doi.org/10.3892/ijo.2018.4626.CrossRefPubMed

12.

Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018;45(5):735–50. https://doi.org/10.1007/s00259-017-3885-z.CrossRefPubMed

13.

Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018;10(431). https://doi.org/10.1126/scitranslmed.aan8840.

Titel: Optimal image guidance for tumor biopsy in non-small-cell lung cancer
verfasst von: Liang Zhao
Qin Lin
Haojun Chen
Publikationsdatum: 02.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04835-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Optimal image guidance for tumor biopsy in non-small-cell lung cancer

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Renal granulomas mimicking as malignant renal masses on F18 FDG PET/CT in a case of urothelial carcinoma

Effect of machine learning re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients

Applied Systems Biology—embracing molecular imaging for systemic medicine

A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT

Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease

Development and characterization of CD54-targeted immunoPET imaging in solid tumors